Gamma Camera Imaging of Platinum in Tumours and Tissues of Patients after Administration of ¹⁹¹Pt-Cisplatin

REFERENCES

• Muggia FM. Testicular cancer and the legacy of chemother-apy. Cancer Chemother Pharmacol 1985 ; 15: 1–5.
   PubMed Web of Science ®Google Scholar
• Johnson NP, Hoeschele JD, Rahn RO. Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodi-ammineplatinum(II) to DNA. Chem Biol Interact 1980; 30: 151–69.
   Google Scholar
• Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends in Biochem Sci 1995; 20: 435–9.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Seki T, Nishikawa K, et al. Antitumor activity and toxicity of serum protein-bound platinum formed from cisplatin. Jpn J Cancer Res (Gann) 1985; 76: 68–74.
   PubMedGoogle Scholar
• Cavalli F, Tschopp L, Sonntag RW, Zimmermann A. A case of liver toxicity following cis-dichlorodiammineplatinum(II) treatment. Cancer Treatments Reports 1978; 62: 2125–6.
   PubMedGoogle Scholar
• Chu G, Mantin R, Shen YM, Baskett G, Sussman H. Mas-sive cisplatin overdose by accidental substitution for carbo-platin. Cancer 1993; 72: 3707–14.
   Google Scholar
• Jonson R, Börjesson J, Mattsson S, Unsgaard B, Wallgren A. Uptake and retention of platinum in patients undergoing cisplatin therapy. Acta Oncol 1991; 30: 315–9.
   PubMed Web of Science ®Google Scholar
• Lange RC, Spencer RP, Harder HC. The antitumor agent cis-Pt(NH3)C12: Distribution studies and dose calculations for 193mPt and 195mPt. J Nucl Med 1972; 14: 191–5.
   Google Scholar
• Smith HS, Taylor DM. Distribution and retention of the antitumor agent 195mPt-cis-dichlorodiammine platinum (II) in man. J Nucl Med 1974; 15: 349–51.
   PubMed Web of Science ®Google Scholar
• Owens SE, Thatcher H, Sharma H, et al. In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum (II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (IV), dis-dichloro-bis-cyclopro-pylamine platinum (III), and cis-diammine 1,1-cyclobutanedi-carboxylate platinum (II) in patients with malignant disease, using a gamma camera. Cancer Chemother Pharmacol 1985; 14: 253–7.
   PubMed Web of Science ®Google Scholar
• Shani J, Bertram J, Russell C, et al. Noninvasive monitoring of drug biodistribution and metabolism: studies with intraar-terial Pt-195m-cisplatin in humans. Cancer Res 1989; 49: 1877–81.
   PubMed Web of Science ®Google Scholar
• Browne E, Firestone RB, Shirley VS. Table of radioactive isotopes, 8th edition. New York: John Wiley and Sons, 1986.
   Google Scholar
• Hoeschele JD, Butler TA, Roberts JA, Guyer CE. Analysis and refinement of the microscale synthesis of the 195mPt-la-beled antitumor drug, cis-dichlorodiammineplatinum(II), cis-DDP. Radiochimica Acta 1982; 31: 27–36.
   Web of Science ®Google Scholar
• Nuclear Medicine Procedure 5, Oak Ridge 19 July 1990, Health Physics Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA.
   Google Scholar
• Riley CM, Stemson LA, Repta AJ. High performance liquid chromatography of cis-dichlorodiammineplatinum(II) using chemically-bonded and solvent-generated ion exchangers. J Chromatography 1981; 217: 405–20.
   Google Scholar
• Snyder WS, Ford MR, Warner GG. NM/MIRD Pamphlet No. 5, revised-estimates of specific absorbed fractions for photon sources uniformly distributed in various organs of a heterogeneous phantom. New York: MIRD Pamphlets, Soci-ety of Nuclear Medicine, 1978.
   Google Scholar
• Williams LR, Leggett RW. Reference values for resting blood flow to organs of man. Clin Phys Physiol Meas 1989; 10: 187–217.
   PubMedGoogle Scholar
• Baer J, Harrison R, McAuliffe CA, Zaki A, Sharma HL, Smith AG. Microscale syntheses of anti-tumour platinum compounds labelled with 191Pt. Intg J Appl Radiat Isot 1985; 36: 181–4.
   PubMedGoogle Scholar
• Iosilevsky G, Israel O, Frenkel A, et al. A practical SPECT technique for quantification of drug delivery to human tu-mors and organ absorbed radiation dose. Semin Nucl Med 1989; XIX: 33–46.
   Google Scholar
• Hecquet B, Vennin P, Fournier C, et al. Platinum concentra-tion in human tumors of head and neck, uterine cervix, and breast following treatment with cisplatin. Cancer Chemother Pharmacol 1985; 15: 310–2.
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Mikhael NZ, Nanji RC, et al. Renal and hepatic concentrations of platinum: relationship to cisplatin time, dose and nephrotoxicity. J Clin Oncol 1985; 3: 1251–6.
   PubMed Web of Science ®Google Scholar
• Uozumi J, Ueda T, Yasumasu T, et al. Platinum accumula-tion in the kidney and liver following chemotherapy with cisplatin in humans. Int Urol Nephrol 1993; 25: 215–20.
   PubMedGoogle Scholar
• Tothill P, Klys HS, Matheson LM, McKay K, Smyth JF. The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. Eur J Cancer 1992; 28: 1358–61.
   Google Scholar
• Sharma H, Thatcher N, Baer J, et al. Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicar-boxylate platinum(II) (CBDCA) in cancer patients. Cancer Chemother Pharmacol 1985; 11: 5–7.
   Web of Science ®Google Scholar
• Thatcher N, Sharma H, Harrisson R, et al. Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclo-porpylamine platinum II, in patients with malignant disease. Cancer Chemother Pharmacol 1982; 9: 13–6.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, van der Vijgh WJF, Klein I, et al. Pharma-cokinetics of free and total platinum species after rapid and prolonged infusion of cisplatin. Clin Pharmacol Ther 1986; 39: 136–44.
   PubMed Web of Science ®Google Scholar